Celltrion’s Kim Emphasizes Innovation As Pipeline Grows

But Company Sees US Biosimilar Interchangeability Designation As ‘Unnecessary’

 
• By David Wallace
  
Dr. HoUng Kim, Head of Medical and Marketing Division at Celltrion Healthcare
HoUng Kim sets out Celltrion’s strategy • Source: Celltrion
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products